Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors

被引：0
|
作者：
Bendell, Johanna C.
Hart, Lowell L.
Pant, Shubham
Infante, Jeffrey R.
Jones, Suzanne Fields
Mohyuddin, Adil
Murphy, Patrick
Patton, Jeffrey
Penley, William Charles
Thompson, Dana Shelton
Burris, Howard A.
机构：
[1] PLLC, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Florida Canc Specialists SCRI, Ft Myers, FL USA
[3] Stephenson Canc Ctr SCRI, Oklahoma City, OK USA
[4] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.475
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
475
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Cohen, Steven J.
    Engstrom, Paul F.
    Lewis, Nancy L.
    Langer, Corey J.
    McLaughlin, Susan
    Beard, Mary
    Weiner, Louis M.
    Meropol, Neal J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (01): : 1 - 5
  • [42] A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors
    Awada, A.
    Gil, T.
    Burk, K.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Matthys, A.
    Piccart, M.
    Hendlisz, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 33 - 34
  • [43] Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+or ER+ metastatic breast cancer.
    Schroder, C. P.
    Pedersen, J. V.
    Chua, S.
    Swanton, C.
    Akimov, M.
    Ide, S.
    Fernandez-Ibarra, C.
    Dzik-Jurasz, A.
    De Vries, E.
    Gaykema, S. B.
    Banerji, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Johnson, Melissa L.
    Yu, Helena A.
    Hart, Eric M.
    Weitner, Bing Bing
    Rademaker, Alfred W.
    Patel, Jyoti D.
    Kris, Mark G.
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) : 1666 - +
  • [45] First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
    Shimomura, Akihiko
    Yamamoto, Noboru
    Kondol, Shunsuke
    Fujiwara, Yutaka
    Suzuki, Shigenobu
    Yanagitani, Noriko
    Horiike, Atsushi
    Kitazono, Satoru
    Ohyanagi, Fumiyoshi
    Doi, Toshihiko
    Kuboki, Yasutoshi
    Kawazoe, Akihito
    Shitara, Kohei
    Ohno, Izumi
    Banerji, Udai
    Sundar, Raghav
    Ohkubo, Shuichi
    Calleja, Elizabeth M.
    Nishio, Makoto
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 531 - 540
  • [46] PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Felip, E.
    Carcereny, E.
    Barlesi, F.
    Gandhi, L.
    Sequist, L. V.
    Kim, S-W.
    Groen, H. J. M.
    Besse, B.
    Kim, D-W.
    Smit, E.
    Akimov, M.
    Avsar, E.
    Bailey, S.
    Ofosu-Appiah, W.
    Garon, E. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 152 - 152
  • [47] Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α
    Stingl, L.
    Niewidok, N.
    Mueller, N.
    Selle, M.
    Djuzenova, C. S.
    Flentje, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (06) : 507 - 515
  • [48] Novel Hsp90 Inhibitor NVP-AUY922 Radiosensitizes Prostate Cancer Cells
    Gandhi, N.
    Wild, A. T.
    Aziz, K.
    Chettiar, S.
    Gajula, R.
    Zeng, J.
    Herman, J.
    Deweese, T. L.
    Hales, R.
    Tran, P. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S178 - S178
  • [49] Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
    Gandhi, Nishant
    Wild, Aaron T.
    Chettiar, Sivarajan T.
    Aziz, Khaled
    Kato, Yoshinori
    Gajula, Rajendra P.
    Williams, Russell D.
    Cades, Jessica A.
    Annadanam, Anvesh
    Song, Danny
    Zhang, Yonggang
    Hales, Russell K.
    Herman, Joseph M.
    Armour, Elwood
    DeWeese, Theodore L.
    Schaeffer, Edward M.
    Tran, Phuoc T.
    CANCER BIOLOGY & THERAPY, 2013, 14 (04) : 347 - 356
  • [50] Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90αRadiosensibilisierender Effekt des neuartigen Hsp90-Inhibitors NVP-AUY922 in Hsp90α-inhibierten humanen Tumorzelllinien
    L. Stingl
    N. Niewidok
    N. Müller
    M. Selle
    C.S. Djuzenova
    M. Flentje
    Strahlentherapie und Onkologie, 2012, 188 (6) : 507 - 517
12345